Pancreatic Cancer Experts Map Treatment Sequencing With Liposomal Irinotecan and Beyond

Season 18 Episode 39  ·  Sep 21, 09:56 PM
Share
Subscribe

Raji Shameem, MD, and Shubham Pant, MD, MBBS, discuss the evolving pancreatic cancer treatment paradigm and novel treatments.

In today’s episode, we spoke with Raji Shameem, MD, and Shubham Pant, MD, MBBS. Dr Shameem is a clinical assistant professor of medicine at the Orlando College of Osteopathic Medicine, an assistant professor of Medicine at the University of Central Florida, and a physician at Orlando Health. Dr Pant is a professor in the Department of Gastrointestinal Medical Oncology and the Department of Investigational Cancer Therapeutics, as well as the director of Clinical Research at The Sheikh Zayed Center For Pancreatic Cancer Research at The University of Texas MD Anderson Cancer Center in Houston.

In our exclusive interview, Drs Shameem and Pant discussed the rapidly evolving pancreatic cancer treatment paradigm, going in-depth on topics like the role of liposomal irinotecan (Onivyde), the FDA approval of daraxonrasib (Rasonque) for patients with metastatic disease, and novel treatments that are in development. The 2 experts also covered which directions they see the pancreatic cancer field moving towards in the future.